Morgan Stanley reaffirmed their overweight rating on shares of Natera, Inc. (NASDAQ:NTRA) in a research note released on Friday morning. They currently have a $16.00 price objective on the medical research company’s stock, up from their previous price objective of $13.00.

A number of other research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Natera from a sell rating to a hold rating in a research note on Friday, September 22nd. Cowen and Company reiterated a buy rating and set a $14.00 price objective on shares of Natera in a research note on Friday, September 1st. BidaskClub upgraded shares of Natera from a sell rating to a hold rating in a research note on Wednesday, August 23rd. Finally, ValuEngine upgraded shares of Natera from a strong sell rating to a sell rating in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $15.05.

Shares of Natera (NASDAQ:NTRA) opened at 14.31 on Friday. The stock’s 50 day moving average price is $13.02 and its 200 day moving average price is $13.02. The stock’s market cap is $761.62 million. Natera has a 52 week low of $7.35 and a 52 week high of $14.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business had revenue of $53.60 million for the quarter, compared to analyst estimates of $50.57 million. During the same quarter last year, the business earned ($0.46) earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts anticipate that Natera will post ($2.03) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Natera, Inc. (NTRA) Earns “Overweight” Rating from Morgan Stanley” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/natera-inc-ntra-earns-overweight-rating-from-morgan-stanley.html.

In related news, insider Jonathan Sheena sold 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.57% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Capital World Investors boosted its holdings in Natera by 0.8% during the second quarter. Capital World Investors now owns 4,222,609 shares of the medical research company’s stock worth $45,858,000 after buying an additional 32,000 shares in the last quarter. Jennison Associates LLC boosted its holdings in Natera by 1.0% during the second quarter. Jennison Associates LLC now owns 2,356,346 shares of the medical research company’s stock worth $25,590,000 after buying an additional 23,473 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Natera by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock worth $24,555,000 after buying an additional 253,344 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Natera by 112.3% during the second quarter. Macquarie Group Ltd. now owns 1,061,880 shares of the medical research company’s stock worth $11,532,000 after buying an additional 561,659 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Natera by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 634,743 shares of the medical research company’s stock worth $6,893,000 after buying an additional 9,223 shares in the last quarter. Hedge funds and other institutional investors own 59.79% of the company’s stock.

Natera Company Profile

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.